Kaplan-Meier estimates of progression-free survival and overall survival (IMAGE)

Science China Press

Kaplan-Meier estimates of progression-free survival and overall survival

Caption

Kaplan-Meier estimates of progression-free survival assessed by RECIST v1.1 per investigator in patients treated with (a) sintilimab versus pembrolizumab as monotherapy, (b) sintilimab versus pembrolizumab plus platinum-based doublet chemotherapy, respectively, as combination therapy, and (c) sintilimab versus pembrolizumab arms including patients who received mono- and combination therapy. Kaplan-Meier estimates of overall survival in monotherapy (d), combination therapy (e), and sintilimab versus pembrolizumab arms (f).

 

Credit

©Science China Press

Usage Restrictions

Use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.